10th Aug 2005 11:03
ReGen Therapeutics PLC10 August 2005 10 August 2005 ReGen Therapeutics announces grant of U.S. patent on use of Colostrinin(tm) topromote induction of Cytokines ReGen Therapeutics Plc ("ReGen" or the "Company"), a company whose productColostrinin(tm) has shown efficacy as a potential treatment for Alzheimer'sdisease, announces that a patent on the use of Colostrinin(tm) as an inducer ofcytokines has been granted by the United States Patent and Trademark Office. Thepatent is owned by the Board of Regents of the University of Texas System and isbased upon long term research at the University of Texas Medical Branch (UTMB)at Galveston, which has been sponsored by ReGen. UTMB has licensed the patentedtechnology to ReGen under the world wide exclusive license agreement that existsbetween the two parties. The new patent covers the use of Colostrinin(tm), its constituent peptides andanalogues to promote cytokine induction. Cytokines are molecules that areinvolved in communication between cells. Potential utility of this patent is expected to be welcomed by people withAlzheimer's disease, because "the induction of cytokines can modulate the immuneresponse in those patients" said Dr. Kruzel, Scientific Consultant to ReGen andAdjunct Professor at the UT Medical School at Houston.* He also added that thepresent invention provides a method of modulating an intracellular signallingthat leads to reduction of cell damaging reactive oxygen species (ROS). Both areimportant in the context of Alzheimer's disease and may go some way to explainthe clinical benefits shown to be associated with ColostrininTM in clinicalstudies". The grant of this patent adds further strength to the intellectual propertyportfolio owned by or licensed to ReGen. ReGen now holds rights to 5 differentpatents relating to Colostrinin(tm); one for the use of Colostrinin(tm) inAlzheimer's disease and other neurodegenerative conditions (granted in 10countries), one for its use as a dietary supplement in combination with othersubstances (granted in UK) and 3 UTMB 'mode of use' patents (granted in USA).The Company has filed a number of other patent applications in relation toColostrinin(tm) its constituent peptides and analogues and these are currentlybeing evaluated by the relevant patent authorities. Commenting on the latest patent grant, Chairman Percy Lomax said "This is nowthe third granted US patent to come from our long standing association with UTMBand represents further progress in our development programme. It remains apleasure to collaborate with such an excellent team of scientists." *Dr. Marian Kruzel is a faculty member at the Department of Integrative Biologyand Pharmacology, the University of Texas, Medical School at Houston. He is aninternationally recognized immunologist with an established interest andexpertise in inflammation and age-related pathophysiology. He is the recipientof numerous grants and a participant in NIH funded projects. Also he serves as areviewer on several scientific journals, including Clinical and ExperimentalImmunology, Cellular and Molecular Biology Letters, and Journal of ExperimentalTherapeutics and Oncology. He is a former chairman of the board of the CancerCoalition of America. Through a consultancy agreement with the Company Dr. Kruzel is responsible tothe Board for scientific research and development and management of thescientific aspects of future clinical development on behalf of the Company. For more information, please contact: Andrew MarshallMarshall Robinson RoeTel No 020 7960 6007 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TILS.L